Taiho Zipalertinib NDA Accepted by FDA for NSCLC
PRINCETON, New Jersey, USA / TOKYO, Japan / CAMBRIDGE, Massachusetts, USA, April 28, 2026 Taiho Oncology, Taiho Pharmaceutical, and...
AI drug discovery Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
PRINCETON, New Jersey, USA / TOKYO, Japan / CAMBRIDGE, Massachusetts, USA, April 28, 2026 Taiho Oncology, Taiho Pharmaceutical, and...
AMSTERDAM, Netherlands & BOSTON, Massachusetts, USA, April 28, 2026 VectorY Therapeutics has announced that it has received authorization from...
